These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 4422210)

  • 1. Minimum acceptable requirements for introduction and marketing of drugs.
    Lasagna L
    Drugs; 1974; 7(6):409-13. PubMed ID: 4422210
    [No Abstract]   [Full Text] [Related]  

  • 2. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
    Simmons HE
    Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901
    [No Abstract]   [Full Text] [Related]  

  • 3. [Proposals for the legal control of the testing and introduction of drugs based on a comparison of drug laws in other countries].
    Burow W; Lüllmann H
    Schriftenr Geb Off Gesundheitswes; 1971; 31():1-64. PubMed ID: 5153578
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
    Gostin LO
    JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
    [No Abstract]   [Full Text] [Related]  

  • 5. To ban or not to ban--that is the question: the constitutionality of a moratorium on consumer drug advertising.
    Schwartz MI
    Food Drug Law J; 2008; 63(1):1-33. PubMed ID: 18561453
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bioavailability, proof of efficacy and their consequences for drug legislation (author's transl)].
    Schnieders B
    Arzneimittelforschung; 1976; 26(1A):158-63. PubMed ID: 947195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Program seeks to enlist physicians to flag questionable promotion of drugs.
    Mitka M
    JAMA; 2010 Jul; 304(1):28-9. PubMed ID: 20606140
    [No Abstract]   [Full Text] [Related]  

  • 8. The Vernacular of Risk--Rethinking Direct-to-Consumer Advertising of Pharmaceuticals.
    Greene JA; Watkins ES
    N Engl J Med; 2015 Sep; 373(12):1087-9. PubMed ID: 26287749
    [No Abstract]   [Full Text] [Related]  

  • 9. Manufacturing uncertainty: adverse effects of drug development for women.
    Peppin P
    Int J Law Psychiatry; 2003; 26(5):515-32. PubMed ID: 14522223
    [No Abstract]   [Full Text] [Related]  

  • 10. To inform or persuade? Direct-to-consumer advertising of prescription drugs.
    Berndt ER
    N Engl J Med; 2005 Jan; 352(4):325-8. PubMed ID: 15673797
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug efficacy and a journal's responsibility.
    Kimmey JR
    Am J Public Health; 1972 Apr; 62(4):461-2. PubMed ID: 5020603
    [No Abstract]   [Full Text] [Related]  

  • 12. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products.
    Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700
    [No Abstract]   [Full Text] [Related]  

  • 13. Extra-label drug use--pharmaceutical industry view.
    Welser JR
    J Am Vet Med Assoc; 1993 May; 202(10):1635-42;discussion 1654-8. PubMed ID: 8514571
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacological and safety aspects of existing requirements and regulations when introducing a new drug.
    Kramer M
    Arzneimittelforschung; 1974 Apr; 24(4):504-8. PubMed ID: 4408328
    [No Abstract]   [Full Text] [Related]  

  • 15. Legal aspects of regulations pertaining to sale and distribution of analytical standards for drugs of abuse. I.
    Evans JG
    J Chromatogr Sci; 1972 May; 10(5):342-6. PubMed ID: 5066301
    [No Abstract]   [Full Text] [Related]  

  • 16. [Medical questions with respect to the introduction of new drug specialties into the German Federal Republic].
    Grillmaier JB
    Int Z Klin Pharmakol Ther Toxikol; 1969 Oct; 2(4):315-31. PubMed ID: 5365590
    [No Abstract]   [Full Text] [Related]  

  • 17. The Food and Drug Administration's requirements for approval of new dental drugs.
    Gilkes CC
    Symp Pharmacol Ther Toxicol Group; 1975 Apr; ():5-12. PubMed ID: 1064180
    [No Abstract]   [Full Text] [Related]  

  • 18. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.
    Cheng CM; Shin J; Guglielmo BJ
    JAMA Intern Med; 2014 Oct; 174(10):1704-5. PubMed ID: 25127107
    [No Abstract]   [Full Text] [Related]  

  • 19. Institute of Medicine's new drug safety report: implications for Canada.
    Cassels A
    CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
    [No Abstract]   [Full Text] [Related]  

  • 20. Medicine goes Madison Avenue: an evaluation of the effect of direct-to-consumer pharmaceutical advertising on the learned intermediary doctrine.
    Allen MC
    Spec Law Dig Health Care Law; 1998 Dec; (236):9-29. PubMed ID: 10187553
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.